LIPID PANEL TEST MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Lipid Panel Test Market Size and Forecast – 2025 to 2032

The Global Lipid Panel Test Market is estimated to be valued at USD 11.82 Bn in 2025 and is expected to reach USD 20.13 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. This significant growth is driven by the increasing prevalence of cardiovascular diseases, rising awareness about cholesterol-related health risks, and advancements in lipid testing technologies that enable faster and more accurate diagnostics.

Key Takeaways of the Global Lipid Panel Test Market

• By test type, the standard lipid profile segment is expected to capture the largest share of the global lipid panel test market, accounting for 84.2% in 2025.
• Within the product type segment, devices lead with an estimated share of 56.7% in 2025.
• Among applications, Hyperlipidemia is projected to emerge as the dominant segment, holding a share of 23.3% in 2025.
• North America is expected to lead the market, holding a share of 39.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.5% in 2025.

Market Overview

A key trend shaping the lipid panel test market is the integration of digital health solutions and point-of-care testing devices, allowing for greater accessibility and convenience in lipid monitoring. Additionally, the growing adoption of personalized medicine and preventive healthcare strategies is fueling the demand for regular lipid profiling. Furthermore, increasing healthcare expenditure in emerging economies and collaborations between diagnostic companies and healthcare providers are contributing to market expansion and innovation.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Lipid Panel Test Market Insights, By Test Type - Widespread Clinical Adoption Drives Standard Lipid Profile Dominance in Test Type

In 2025, the standard lipid profile segment is projected to be the major contributor to the global lipid panel test market with a share of 84.2% as it is the primary method used in routine cardiovascular risk assessment. It gives the total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol, thus allowing a quick and easy look at the lipid metabolism. The health organizations’ approval and recommendation made it very easy and widespread to help detect dyslipidemia, which is one of the main causes of CVD. It is also used in clinical practice mainly because it can help monitor not only the patients’ health status but also the effectiveness of the lipid-lowering treatments, such as statins, that the patients have been receiving.

In April 2024, Canadian Cardiovascular Society announced its support for the CCS National Lipid Screening Awareness Campaign, aiming to address Atherosclerotic Cardiovascular Disease (ASCVD), cholesterol, and dyslipidemia guidelines. This initiative is part of a broader effort to raise awareness about lipid screening and its importance in managing heart health. The campaign underscores the critical role of early detection in preventing cardiovascular diseases, encouraging more widespread testing and engagement with health professionals.

Lipid Panel Test Market Insights, By Product Type - Devices Segment Leads the Market Driven by Rapid Technological Advancements and Full Automation Integration

Looking at the product type segment, devices will hold an estimated share of 56.7% in 2025, and this is mainly due to technological innovations plus the increasing demand for faster and more accurate testing of lipid panels. The devices segment can be seen as the area that houses the tools needed for lipid measurement which is the backbone of laboratory and clinical diagnostics.

The experience that has been gained with automated analyzers has led to a significant increase in lipid test throughput, reproducibility, and accuracy. This becomes especially important in regions with rising cardiovascular disease prevalence to cope with the resulting increase in patient volumes. Automated systems simplify the lipid testing process by combining sample handling, analysis, and data reporting, thereby reducing the time allowed for taking clinical decisions to the point of necessity.

Lipid Panel Test Market Insights, By Application - Prevalence of Hyperlipidemia Elevates Its Application Segment Share

Based on application, Hyperlipidemia is projected to lead the global lipid panel test market with a share of 23.3% in 2025 because of its widespread occurrence and pivotal part in cardiovascular risk creation. Hyperlipidemia is the condition of having a high concentration of lipids in the blood, which is a major risk factor for atherosclerosis, coronary artery disease, stroke, and other diseases of the heart and blood vessels that can be modified through treatment.

The lipid panel test is a cornerstone in diagnosing hyperlipidemia, facilitating early identification and enabling timely therapeutic interventions. Healthcare providers rely on lipid testing not only to confirm dyslipidemia but also to tailor treatment strategies including lifestyle modification and pharmacotherapy.

Regional Insights

To learn more about this report, Download Free Sample

North America Lipid Panel Test Market Analysis and Trends

In 2025, North America is projected to account for 39.3% of the global lipid panel test market. This dominance is driven by the region’s well-established healthcare infrastructure, the widespread adoption of advanced diagnostic technologies, and strong government initiatives promoting preventive healthcare. The presence of significant developers such as Abbott, Roche, and Quest pan-India strengthens the lift of lipid testing not only through their availability and innovation but also through promoting their acceptance in the market.

In January 2025, Roche Diagnostics received U.S. FDA 510(k) clearance for its Tina-quant Lipoprotein (a) Gen.2 Molarity assay, the first U.S. Lipid Panel Test to measure Lp(a) in molar units. This test provides more accurate cardiovascular risk assessment by using nanomoles per liter (nmol/L) instead of mass units.

Asia Pacific Lipid Panel Test Market Analysis and Trends

Asia Pacific exhibits the fastest growth in the lipid panel test market, driven by rising healthcare expenditure with an estimated share of 24.5% in 2025, increasing incidence of lifestyle diseases, and expanding health insurance coverage across emerging economies like India, China, and Southeast Asian countries. Government initiatives aimed at strengthening healthcare infrastructure and increasing diagnostic accessibility are accelerating market expansion.

Furthermore, increasing awareness concerning cardiovascular health and the availability of better screening have been the key drivers of demand. The market ecosystem is able to benefit from the mix of global giants like Siemens Healthineers, Danaher Corporation as well as the local manufacturers who are working to come up with cost-effective test solutions.

Global Lipid Panel Test Market Outlook for Key Countries

U.S. Lipid Panel Test Market Trends

The lipid panel test market in the U.S. is the largest and also the most advanced with biomedical research and development being the second-highest investment in the country, plus almost all patients being given the present diagnostic technologies easily. Through the support of the government, strong insurance coverage is provided to major players such as Abbott and Quest, who offer state-of-the-art lipid panel testing services. The country's regulatory framework allows rapid product approvals, which, in turn, fosters innovation and quick adoption of new lipid testing platforms in clinical settings.

In the U.S., Abbott Laboratories and Quest Diagnostics are key players driving the adoption of lipid panel tests. Abbott Laboratories offers the ARCHITECT Lipid Panel, a comprehensive testing platform used in clinical labs to measure cholesterol levels accurately. Similarly, Quest Diagnostics provides advanced lipid panel testing services, benefiting from the widespread availability of health insurance and government programs like Medicare that emphasize preventive care.

Germany Lipid Panel Test Market Trends

Germany's market for lipid panel tests is supported by an excellent healthcare system that is extremely well recognized for its technological innovation and the top-notch quality of its clinical diagnostics. The government's initiatives to improve the diagnosis of chronic diseases at the earliest stages combined with the efficient reimbursement systems make it easy for the market to grow. Moreover, being the most favorable location for the pharmaceutical and diagnostic industry in Europe, Germany also has a positively influencing impact on the market dynamics.

In Germany, Roche Diagnostics leads the market with its Cobas series of lipid testing platforms, widely used across clinical and research settings. Roche’s innovative testing technologies are backed by the country's strong healthcare system, which promotes early disease detection. With Germany’s comprehensive reimbursement system, lipid panel tests are made accessible, ensuring high adoption rates in the market.

China Lipid Panel Test Market Trends

The modernization of healthcare in China, along with the government’s focus on reducing the impact of heart-related ailments, are the major causes for the increase in the demand for lipid panel tests. Urbanization and increasing numbers of people joining the middle-class are leading to more and more people going for preventive health check-ups. The recognition and support given by the government to health facilities in rural areas further stretch the market.

Siemens Healthineers and Danaher Corporation are expanding their footprint in China’s growing lipid panel test market. Siemens Healthineers has developed the Atellica Solution, an advanced platform used for lipid testing in clinical environments. These companies are benefiting from China's healthcare modernization and government efforts to improve rural healthcare access, expanding the lipid panel test market.

India Lipid Panel Test Market Trends

The lipid panel test market in India is witnessing a fast transformation because of the rapidly increasing cases of metabolic and cardiovascular diseases along with the healthcare infrastructure being improved. Diagnostic service providers that are present locally and international companies like Trivitron Healthcare are making respiratory tests widely available at affordable prices. Health insurance schemes are getting wider coverage along with government campaigns to increase public awareness about early disease detection are all working together to cause the expansion of lipid panel tests’ adoption.

In India, Trivitron Healthcare is a prominent player in the lipid panel test market, offering cost-effective solutions to increase accessibility. Trivitron Healthcare provides diagnostic equipment and lipid testing kits that help raise awareness and promote early detection of cardiovascular diseases. Additionally, government initiatives like Ayushman Bharat and favorable trade policies are helping increase the adoption of lipid tests in the country.

End User Feedback and Unmet Needs – Global Lipid Panel Test Market

• End users, particularly healthcare providers and diagnostic labs, have praised the efficiency of integrated systems that enhance testing speed and simplify data management. These systems help reduce turnaround times and improve decision-making in critical care. However, a common concern is the high cost of advanced lipid panel tests, particularly in rural or underserved areas, where limited access to technology delays early intervention and prevention.
• Unmet needs largely revolve around affordability, accessibility, and customization. There is a strong demand for cost-effective testing solutions that do not compromise on accuracy, as well as more adaptable platforms suited to various healthcare settings. Addressing these needs would improve access to vital health screenings, enhance customer retention, and create growth opportunities by encouraging innovation in affordable and scalable testing technologies.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In August 2025, Novartis announced positive results from the V-DIFFERENCE Phase IV study, which evaluated Leqvio (inclisiran) in patients with high cholesterol who had not reached their LDL-C goals with lipid-lowering therapy and lipid panel tests. The study showed that 85% of patients on Leqvio achieved LDL-C targets within 90 days, compared to just 31% with placebo. Additionally, patients on Leqvio experienced 43% fewer muscle-related adverse events, demonstrating the drug's potential to improve outcomes without increasing muscle pain, a common side effect of statins.
• In June 2025, QRIS Health, a trusted diagnostic lab in Delhi, India launched a new mobile app designed to simplify healthcare by enabling easy test bookings, free home sample collection, and instant digital reports. The app includes features like booking pathology tests such as Lipid Profile, Liver Function Test, and specialized health checkups, along with scheduling imaging tests and connecting with nearby doctors. First-time users can enjoy a 40% discount, making healthcare more accessible and convenient than ever before.
• In September 2024, the Association for Diagnostics & Laboratory Medicine (ADLM) released new guidance on lipid testing to help improve cardiovascular disease care. The updated guidelines clarify the use of lipid panels, including total cholesterol, triglycerides, HDL-C, and LDL-C, to better assess heart disease and stroke risk. The guidance also recommends using more accurate calculation methods and relaxing fasting requirements for most patients to make testing more accessible.
• In September 2024, the Family Heart Foundation launched Cholesterol Connect, offering free at-home lipid screening and personalized support to help individuals manage cardiovascular health. Sponsored by Amgen, the program provides lipid panel tests, including LDL-C and lipoprotein(a) (Lp(a)), and personalized guidance from Family Heart Care Navigators. The initiative is open to the public, regardless of insurance, empowering individuals to better understand and address heart disease risks.

Top Strategies Followed by Global Lipid Panel Test Market Players

• Big companies allocate a lot of their resources to research and development with the aim of coming up with new and better products for lipid panel testing, thereby remaining ahead of both technological and regulatory changes. Their accuracy, speed, and usability enhancements are drawing consumer loyalty and sustaining brand reputation. Their collaboration with industry leaders and OEMs is not only widening their global presence but also allowing them to gain access to and integrate technologies that are complementary.
  • Major players such as Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific, and Ortho Clinical Diagnostics are also advancing lipid testing technologies through innovation and system integration. Beckman Coulter is upgrading its AU and DxC analyzers to improve automation and analytical precision; Thermo Fisher is enhancing reagent sensitivity and workflow efficiency for clinical chemistry platforms; and Ortho Clinical Diagnostics is expanding the use of its VITROS dry-slide technology to ensure consistent, contamination-free lipid testing.

• The global lipid panel test market is predominantly ruled by mid-tier players who follow a specific cost-effective approach. Such players are focusing mainly on the low-priced segments, without sacrificing too much on the quality and performance of the products. Their products are usually mid-priced and clinically accurate, which is why the testing of lipid panels is becoming more and more frequent in the healthcare system and the consumers of developing countries and budget-conscious market segments.
  • Siemens Healthineers is a notable mid-tier player with its Dimension EXL 200 system, which balances affordability with clinical precision. Siemens Healthineers specifically targets diagnostic centers and hospitals in emerging markets like India and Southeast Asia, where affordability and efficiency are key. Another example is Bio-Rad Laboratories, which provides mid-range products like the Bio-Rad Laboratories Clinical Chemistry Analyzer.

• Small-scale players in the lipid panel test market find their own way of existence most of the time by being the ones who have the best product features, innovative testing methods, or unique value propositions that make them different from the big players. These companies regularly grasp the latest technologies such as point-of-care testing devices, multiplex lipid assays, or digital integration capabilities that are specifically targeted at particular consumers or diagnostic trends.
  • Everlywell is a prime example of a small-scale player disrupting the lipid panel test market with its at-home testing kit that allows users to collect their lipid panel samples and receive results via an online platform. This innovative approach aligns with the rise of telehealth and consumer-driven diagnostics. Another small-scale player, Lipid Analytics, offers cutting-edge multiplex lipid assays, which allows multiple lipid markers to be tested in a single sample.

Market Report Scope

Lipid Panel Test Market Report Coverage

Lipid Panel Test Market Dynamics

To learn more about this report, Download Free Sample

Lipid Panel Test Market Driver - Increasing Prevalence of Cardiovascular Diseases

The worldwide increasing rate of cardiovascular diseases (CVDs) is the main reason for the growing demand for lipid panel tests. With improvements in medical facilities and growing health awareness, more people are undergoing regular health check-ups. As a result, lipid panel tests are increasingly being recognized as vital tools for the early detection and management of dyslipidemia, a key risk factor for cardiovascular diseases such as coronary artery disease, stroke, and hypertension. The rising incidence of such lifestyle-related diseases is pushing the need for regular lipid monitoring as obesity, diabetes, and sedentary lifestyle are making cholesterol and triglyceride levels go up in the population.

In December 2023, a new study published in the Journal of the American College of Cardiology revealed that cardiovascular diseases (CVDs) continue to be the leading cause of global death, with an estimated 19.8 million deaths in 2022. High blood pressure, high cholesterol, unhealthy diets, and air pollution are key risk factors, especially in regions like Asia Pacific, Europe, Africa, and the Middle East.

Lipid Panel Test Market Opportunity - Rising Adoption of Home-Based Lipid Testing Kits

The expanding global lipid panel test market is being greatly supported by the increasing use of home-based lipid testing kits. People have become more aware of cardiovascular diseases and the need for regular lipid monitoring, which has led them to look for testing options that are more convenient and closer to them. The home-based lipid testing kits permit people to carry out lipid panel tests at their homes, giving them fast and trustworthy results without the hassle of visiting the clinic frequently. This convenience is very much in sync with the increasing trend of personalized healthcare and digital health solutions.

In September 2024, the Family Heart Foundation launched Cholesterol Connect, a program offering free at-home blood lipid panel testing and personalized care navigation to help individuals monitor their cholesterol levels and cardiovascular disease (CVD) risks. The initiative, supported by Amgen, aims to raise awareness of high LDL-C and lipoprotein(a) (Lp(a)) levels, which are major contributors to heart disease and often go undiagnosed.

Analyst Opinion (Expert Opinion)

• The lipid panel test market is growing not only because of the technological advancements in testing methods but also because of the awareness about the necessity for preventive healthcare. The increasing number of heart disease cases worldwide is causing more and more people to take lipid tests which are further supported by the authorities that encourage early detection. Meanwhile, there are some obstacles such as the cost factor that the insurance companies are causing and the lack of healthcare facilities in some regions. The home-testing options that are being developed are one of the factors that might disrupt the regular testing procedures but they are also considered to be new solutions.
• Scientific Sessions of American Heart Association and Congress of European Society of Cardiology organized by cardiovascular diseases have provided a platform for discussions that influence market trends and regulatory changes. The WHO’s Global Hearts Initiative and the developments of firms like Abbott and Roche are enabling more lipid screening programs that are, in turn, making testing easier to access. The above-mentioned changes are going to be one of the most important factors influencing the global market in the coming years.

Market Segmentation

• Test Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Standard Lipid Profile
    • Total Cholesterol
    • Triglycerides
    • Low-Density Lipoprotein (LDL) Cholesterol
    • High-Density Lipoprotein (HDL) Cholesterol
  • Advanced Lipid Testing
    • LDL Particle Number (LDL-P)
    • Apolipoprotein B (ApoB)
    • Lipoprotein(a) (Lp(a))
    • Others (HDL Subclasses, VLDL Cholesterol etc.)
• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Devices
    • Automated Analyzers
    • Point-of-Care Testing Devices
    • Spectrophotometers
    • Others
  • Reagents and Kits
    • Cholesterol Test Kits
    • HDL and LDL Kits
    • Triglyceride Test Kits
    • Test Strips
    • Other Product Types
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Hyperlipidemia
  • Hypertriglyceridemia
  • Familial Hypercholesterolemia
  • Hypo Lipoproteinemia
  • Tangier Disease
  • Atherosclerosis
  • Other Lipid Disorders
• Prescription Mode Insights (Revenue, USD Bn, 2020 - 2032)
  • Prescription-Based Testing
  • Over-the-Counter (OTC) Testing
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Pathology Laboratories
  • Diagnostic Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Academic and Research Institutes
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott Laboratories
  • Beckman Coulter Inc.
  • Hoffmann-La Roche Ltd.
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific Inc.
  • Siemens Healthcare GmbH
  • Bio-Rad Laboratories Inc.
  • Nova Biomedical Corporation
  • SD Biosensor, Inc.
  • PTS Diagnostics
  • Horiba Medical
  • Elitech Group
  • Menarini Group
  • VivaChek Biotech (Hangzhou) Co., Ltd.
  • Mico Bio Med

Sources

Industry Stakeholders

• Hospital laboratory heads
• Diagnostic center managers
• Clinical chemists
• Pathologists
• Molecular biologists
• Procurement heads across leading global markets

End-users

• Physicians
• Patients undergoing lipid testing
• Healthcare providers
• Insurance companies
• Public health organizations
• Regulatory bodies

Government and International Databases

• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• National Institutes of Health (NIH)
• European Medicines Agency (EMA)
• U.S. Food and Drug Administration
• Indian Council of Medical Research (ICMR)

Trade Publications

• Clinical Chemistry
• Journal of Clinical Lipidology
• American Journal of Clinical Pathology
• Journal of Clinical Laboratory Analysis
• Laboratory Medicine
• Clinical Biochemistry

Academic Journals

• The Lancet
• Journal of the American Medical Association (JAMA)
• New England Journal of Medicine (NEJM)
• Circulation
• European Heart Journal
• Atherosclerosis

Reputable Newspapers

• The New York Times
• The Guardian
• The Washington Post
• The Times of India
• The Hindu
• Financial Times

Industry Associations

• American Heart Association (AHA)
• American College of Cardiology (ACC)
• European Society of Cardiology (ESC)
• Indian Medical Association (IMA)
• Cardiological Society of India (CSI)
• International Atherosclerosis Society (IAS)

Public Domain Resources

• National Library of Medicine
• Open Access Journals
• Government Health Portals
• World Bank Health Data
• UNICEF Health Statistics
• National Health Service (NHS) Resources

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years